Stephanie Noviello

Dr. Stephanie Noviello


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in The Lancet
Verified
Journal Article
Closed access
CKCheryl Keech
Cheryl Keech
VMVicki E Miller
Vicki E Miller
BRBarbara Rizzardi
Barbara Rizzardi
CHChristopher Hoyle
Christopher Hoyle
MPMelinda J Pryor
Melinda J Pryor
CLCamille Locht
Camille Locht

30 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
PGPeter Goldstein
Peter Goldstein
TGTania Gensale
Tania Gensale
SHShannon Harris
Shannon Harris
TGTina Green
Tina Green
SNStephanie Noviello
Stephanie Noviello
LGLuc Gagnon
Luc Gagnon
Background/Objectives: Pertussis, caused by Bordetella pertussis, remains a global health problem, despite high vaccine coverage. In countries with high acellular pertussis vaccine (aPV) coverage, pertactin-negative B. pertussis strains emerged due to vaccine pressure on the sole bactericidal target of aPVs. In contrast, the live attenuated intranasal vaccine BPZE1 induces bactericidal antibodies to multiple antigenic targets that kill pertactin-positive and pertactin-negative B. pertussis strains. Here, we developed two high-throughput human complement-mediated serum bactericidal assays (SBA) using clinical samples to demonstrate bactericidal activity against B. pertussis. Methods: Assay accuracy, precision, linearity, range and robustness of the SBAs against pertactin-positive and pertactin-negative B. pertussis strain B1917 were determined using a panel of commercial and clinical trial samples. The assay was used to analyze a cohort of BPZE1 and tetanus–diphtheria–acellular pertussis (Tdap) vaccinee samples at baseline and 28 days post-vaccination from a phase 2b clinical trial. Results: Inter- and intra-assay variability of both assays had coefficients of variation for repeatability < 20% and for intermediate precision of 0.98) between bactericidal titers and serum dilutions. On clinical samples, BPZE1 induced similar bactericidal activity as Tdap against pertactin-positive B. pertussis, despite inducing lower anti-aP antigen IgG concentrations than Tdap. Additionally, BPZE1 induced serum bactericidal activity against pertactin-negative B. pertussis, while Tdap did not. Conclusions: High-throughput SBAs were developed and qualified against pertactin-positive and pertactin-negative B. pertussis, enabling measurement of 120 samples per day per analyst. These assays will support clinical development of next-generation pertussis vaccines, including BPZE1.